

Curriculum Vitae



■ Personal Information

Name: Julia Höfer
Date/Place of birth: 17/04/1982; Innsbruck
Address: Experimental Urology, Department of Urology,
Innsbruck Medical University
Anichstrasse 35, 6020 Innsbruck, Austria
Nationality: Austria
E-Mail adresse: julia.hoefer@i-med.ac.at
Phone: +4351250426449

■ Main Areas of Research

Endocrine related malignancies, prostate cancer, breast cancer, cytokine signaling, hormone signaling, therapy resistance.

■ Education

11/2009-12/2013 PhD thesis within the doctoral college *Molecular Cell Biology and Oncology* (MCBO), Innsbruck Medical University; Degree: PhD
2006-2009 Masters studies in Molecular Biology, University of Innsbruck
2003-2006 Bachelor studies in Biology, University of Innsbruck;
2000-2003 Studies in Human Medicine, Innsbruck Medical University

■ Professional Experience

Since 01/2014 Postdoctoral researcher at the Department of Urology, Innsbruck Medical University
02/2015-05/2015 Supervision of the student Kristina Trattnig (technician bachelor thesis; topic: “Expression and function of TLR4 in docetaxel resistant cells”)
02/2014-05/2014 Supervision of the student Amra Civic (technician bachelor thesis; topic: “Expression of PIAS1 in breast cell lines”)
11/2009-12/2013 PhD position at the Department of Urology, Innsbruck Medical University, Innsbruck, Austria; Topic: „*The Oncogenic Role of PIAS1 and SOCS2 in Prostate Cancer*“ (Supervisor: Dr. Zoran Culig)

01/2013-02/2013	Secondment at the Institute of Pathology, University Hospital Bonn, Bonn, Germany; (Supervisor: Dr. Glen Kristiansen)
03/2012-07/2012	Supervision of the student Melanie Nagl (technician bachelor thesis; topic: "Expression of SOCS1/3 in stromal prostate cells")
07/2008-07/2009	Master thesis; Gene Therapy Laboratory, Internal Medicine I, Innsbruck Medical University; Topic: „ <i>The thyromimetic T-0681 – studies in knock-out mice</i> “ (Supervisor: Dr. Andreas Ritsch)
2000-2008	Half-time job as sales assistant; T-Mobile Austria

■ Fundings

1. 2015: Hertha Firnberg Grant (FWF, Land Tirol), 223.500 Euro (ongoing, 3 years)

Project title: The role of PIAS1 in cancer radiotherapy response

2. 2013: Funding of a Secondment at the University Hospital Bonn; Provided by Innsbruck Medical University

Topic: Methylation status of SOCS1/2/3 in prostate cancer tissue

■ Scientific Awards

1. Dissertationspreis Österreichische Krebshilfe/Tirol 2014 (ÖKH-KG/Tirol)

2. Sanofi – Aventis Award 2012 for outstanding publication

“PIAS1 is increased in human PCa and enhances proliferation through inhibition of p21”

3. Forschungs- und Innovationspreis für Urologische Onkologie 2012

Awarded by the *German Society for Urology (DGU)* for outstanding publication in 2012:

“PIAS1 is increased in human PCa and enhances proliferation through inhibition of p21”

4. Travel award for 21th ESUR / 65th DGU meeting; September 2013; Dresden, Germany

In acknowledgement of an outstanding abstract entitled “*SOCS2 expression increases during prostate cancer progression and is regulated by androgens*”

5. Travel award for the 20th ESUR meeting; October 2012; Strasbourg, France

In acknowledgement of an outstanding abstract entitled “EMT - A possible loop-hole for prostate cancer cell survival”

■ Selected Oral Presentations at international meetings

1. Oral presentation at the 21th ESUR meeting (EAU Section of Urological Research) in collaboration with the 65th Congress of the DGU (German Society for Urology); 09/2013; Dresden, Germany

Title: SOCS2 expression increases during PCa progression and is regulated by androgens

- 2. Oral presentation at the 20th ESUR meeting, 10/2012; Strasbourg, France**
Title: EMT - A possible loop-hole for prostate cancer cell survival
- 3. Oral presentation at the 64. Congress of the DGU (German Society for Urology); 09/2012; Leipzig, Germany**
Title: PIAS1 is increased in prostate cancer and enhances proliferation through inhibition of p21
- 4. Oral presentation at the 35. Meeting of the C.E. Alken Society; 11/2011, Wiesbaden, Germany**
Title: PIAS1 is increased in prostate cancer and enhances proliferation through inhibition of p21
- 5. Oral presentation at the 19th ESUR meeting, 09/ 2011; Innsbruck, Austria**
Title: Functional significance of PIAS1 in prostate cancer

■ Selected Poster Presentations at international meetings

- 1. Poster presentation at the 22th ESUR meeting (EAU Section of Urological Research; September 2015, Nijmegen, The Netherlands**
Title: Upregulation of AR expression in Enzalutamide resistant PCa cell lines
- 2. Poster presentation at the 21th ESUR meeting (EAU Section of Urological Research; October 2014, Glasgow, Scotland, UK**
Title: PIAS1 correlates with AR expression in prostate cancer and acts as a positive feedback regulator of androgen receptor signaling
- 3. Poster presentation at the annual meeting of the “Society for Basic Urological Research” (SBUR); 11/2012; Miami (FL), USA**
Title: SOCS2 is expressed in prostate cancer cells and is regulated by androgens
- 4. Poster presentation at the AACR meeting “Advances in prostate cancer research”, 02/2012, Orlando (FL), USA**
Title: PIAS1 is increased in prostate cancer and enhances proliferation through inhibition of p21

■ Publications in peer-reviewed Journals

1. Critical Role of Androgen Receptor in PCa cell Resistance to New Generation Antiandrogen Enzalutamide

Julia Hoefler, Philipp Ofer, Mohammady Akbor, Zoran Culig, Helmut Klocker* and Isabel Heidegger*

Oncotarget, in revision, May 2016

2. SOCS3 influences AR activity and stem cell-associated genes during anti-androgen treatment in prostate cancer

Florian Handle, Holger H. H. Erb, Birgit Luef, Julia Hoefler, Dimo Dietrich, Walther Parson, Glen Kristiansen, Frédéric R. Santer*, and Zoran Culig*

Mol Cancer Res. 2016 Apr 6. pii: molcanres.0495.2015

3. PIAS1 correlates with AR expression in prostate cancer and acts as a positive feedback regulator for AR signaling

Martin Pühr, Julia Hoefler, Andrea Eigentler, Dimo Dietrich, Geert van Leenders, Barbara Uhl, Marije Hoogland, Florian Handle, Bettina Schlick, Hannes Neuwirt, Verena Sailer, Glen Kristiansen, Helmut Klocker, and Zoran Culig

Oncogene. 2015 Aug 10. doi: 10.1038/onc.2015.292.

4. Is Eotaxin-1 a serum and urinary biomarker for prostate cancer detection and recurrence?

Heidegger I, Höfer J, Luger M, Pichler R, Klocker H, Horninger W, Steiner E, Jochberger S, Culig Z.

Prostate. 2015 Aug 26. doi: 10.1002/pros.23086

5. Differential Utilization of Dietary Fatty Acids in Benign and Malignant Cells of the Prostate

Andrea Düregger, Bernd Schöpf, Theresa Eder, Julia Höfer, Erich Gnaiger, Astrid Aufinger, Lukas Kenner, Bernhard Perktold, Reinhold Ramoner, Helmut Klocker, Iris E. Eder

PLoS One. 2015 Aug 18;10(8):e0135704. doi: 10.1371/journal.pone.0135704

6. PIAS1 is a crucial factor for prostate cancer cell survival and a valid target in docetaxel resistant cells

Martin Pühr, Julia Hoefler, Hannes Neuwirt, Iris E. Eder, Johann Kern, Georg Schäfer, Stephan Geley, Isabel Heidegger, Helmut Klocker, and Zoran Culig

Oncotarget. 2014 Dec; 15;5(23):12043-56.

7. Fibrates ameliorate the course of bacterial sepsis by promoting neutrophil recruitment via CXCR2

Manfred Nairz , Kristina Duwensee , Kristina Auer , Andrea Schroll , Christiane Heim , Clemens Feistritzer , Julia Hoefler , Ingrid Heller , Petra Pallweber , Xiaorong Li , Markus Theurl, Egon Demetz , Anna Wolf , Dominik Wolf , Philipp Eller , Andreas Ritsch , Guenter Weiss

Embo Molecular Medicine. 2014 Apr 22;6(6):810-20. doi: 10.1002/emmm.201303415

8. SOCS2 correlates with malignancy and exerts growth-promoting effects in prostate cancer.

Hoefler J, Kern J, Ofer P, Eder I.E, Schäfer G, Dietrich D, Kristiansen G, Geley S, Gunsilius E, Klocker H, Culig Z, Pühr M.

Endocrine Related Cancer. 2014 Jan 30;21(2):175-87. Doi: 10.1530/ERC-13-0446

9. Epithelial to Mesenchymal Transition Leads to Docetaxel Resistance in Prostate Cancer and is Mediated by Reduced Expression of miR-200c and miR-205

Martin Puhr, **Julia Hoefler**, Georg Schäfer, Holger H.H. Erb, Su Jung Oh, Helmut Klocker, Isabel Heidegger, Hannes Neuwirt, and Zoran Culig

The American Journal of Pathology. 2012 Dec;181(6):2188-201. Doi: 10.1016/j.ajpath.2012.08.011

10. PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21

Julia Hoefler, Georg Schäfer, Helmut Klocker, Holger H.H. Erb, Ian G. Mills, Ludger Hengst, Martin Puhr, and Zoran Culig

American Journal of Pathology. 2012 May;180(5):2097-107. Doi: 10.1016/j.ajpath.2012.01.026

11. Soluble gp130 regulates Prostate Cancer Invasion and Progression in an Interleukin-6 Dependent and Independent Manner

Shahrokh F. Shariat, Thomas F. Chromecki, **Julia Hoefler**, Christopher E. Barbieri, Douglas S. Scherr, Pierre I. Karakiewicz, Claus G. Roehrborn, Francesco Montorsi, Zoran Culig, and Ilaria T. Cavarretta

Journal of Urology. 2011 Nov;186(5):2107-14. Doi: 10.1016/j.juro.2011.06.048

12. The liver-selective thyromimetic T-0681 promotes reverse cholesterol transport and prevents atherosclerosis development in mice

Ivan Tancevski, Egon Demetz, **Julia Hoefler**, Andreas Wehinger, Philipp Eller, Kristina Duwensee, Kristina Auer, Regina Karer, Julia Huber, Wilfried Schgoer, Catherine Fievet, Frans Stellaard, Mats Rudling, Josef R Patsch, Andreas Ritsch

PLoS One. 2010 Jan 15;5(1):e8722. Doi: 10.1371/journal.pone.0008722

13. The thyromimetic T-0681 protects from atherosclerosis

Tancevski I, Wehinger A, Demetz E, **Hoefler J**, Eller P, Huber E, Stanzl U, Duwensee K, Auer K, Schgoer W, Kuhn V, Fievet C, Stellaard F, Rudling M, Foeger B, Patsch JR, Ritsch A.

Journal of Lipid Research. 2009 May;50(5):938-44. Doi: 10.1194/jlr.M800553-JLR200

■ **Invited PR articles**

1. Title: „Wichtiger Schalter des Zellzyklus gestört“

Author: Hoefler, J.

Urologische Nachrichten, 2/2013 (12-13)

Publisher: Biermann Medizin

2. Title: „Fehlregulierte Signalwege identifizieren“

Author: Hoefler, J.

CliniCum Urologie, 12/2012 (4/12CC; 16-17)

Publisher: Medizin Medien Austria